Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

The epigenetics pipeline

Nature Reviews Drug Discovery volume 12, pages 661–662 (2013)Cite this article

Subjects

Epigenetic mechanisms in disease

To date, the most thoroughly investigated therapeutic area in terms of epigenetics is cancer, in which both hypomethylation and hypermethylation of DNA have been linked to tumour growth. Aberrant patterns of histone marks have also been shown to have a role in oncogenesis: hypoacetylation and hypermethylation of histones H3 and H4 can inhibit genes involved in tumour suppression, independently of altered DNA methylation1.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Epigenetic drugs by phase of clinical development and mechanism of action.

References

  1. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159 (2008).

    Article  CAS  Google Scholar 

  2. Arrowsmith, C. H. et al. Epigenetic protein families: a new frontier for drug discovery. Nature Rev. Drug Discov. 11, 384–400 (2012).

    Article  CAS  Google Scholar 

  3. Burridge, S. Drugging the epigenome. Nature Rev. Drug Discov. 12, 92–93 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Trinity Partners, 675 Third Avenue, 20th Floor, New York, 10017, New York, USA

    Vivian A. DeWoskin & Ryan P. Million

Authors
  1. Vivian A. DeWoskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan P. Million
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Vivian A. DeWoskin or Ryan P. Million.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeWoskin, V., Million, R. The epigenetics pipeline. Nat Rev Drug Discov 12, 661–662 (2013). https://doi.org/10.1038/nrd4091

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4091

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research